Active	Status	Sponsor type	Region	Phase	Filter
5 Active 8 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
rocilinostat (ACY-1215) / Regenacy
NCT03176472: Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy	Completed	2	282	US	ricolinostat, ACY-1215, Placebo	Regenacy Pharmaceuticals LLC	Painful Diabetic Peripheral Neuropathy	10/22	04/23
NCT01997840 / 2014-002338-29: ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma EHA 2016 May 2016 - May 2016: EHA 2016 In combination with ricolinostat and dexamethasone in multiple myeloma at ASH 2015 Dec 2015 - Dec 2015: In combination with ricolinostat and dexamethasone in multiple myeloma at ASH 2015 In combination with pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma at EHA 2015 Jun 2015 - Jun 2015: In combination with pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma at EHA 2015 More	Terminated	1/2	103	US	ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone, Pomalyst, Ricolinostat, Dexamethasone	Celgene	Multiple Myeloma	02/24	02/24
NCT05193851: Evaluate the Safety and Pharmacokinetics of Ricolinostat	Completed	1	12	RoW	ricolinostat	Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.	Peripheral Nervous System Diseases	01/22	01/23
NCT05229042: A Study to Investigate the Safety and Efficacy of Ricolinostat	Completed	1	10	RoW	Ricolinostat, Placebo	Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.	Peripheral Nervous System Diseases	11/23	11/23
NCT02787369: ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL	Active, not recruiting	1	3	US	ACY-1215, Ricolinostat, Ibrutinib, Imbruvica, Idelalisib, Zydelig	Dana-Farber Cancer Institute, Acetylon Pharmaceuticals Incorporated	Recurrent Chronic Lymphoid Leukemia	04/26	04/27
RCY-1497 / Regenacy
No trials found
ACY-957 / Regenacy
No trials found
RCY-1305 / Regenacy
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
rocilinostat (ACY-1215) / Regenacy
NCT03176472: Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy	Completed	2	282	US	ricolinostat, ACY-1215, Placebo	Regenacy Pharmaceuticals LLC	Painful Diabetic Peripheral Neuropathy	10/22	04/23
NCT01997840 / 2014-002338-29: ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma EHA 2016 May 2016 - May 2016: EHA 2016 In combination with ricolinostat and dexamethasone in multiple myeloma at ASH 2015 Dec 2015 - Dec 2015: In combination with ricolinostat and dexamethasone in multiple myeloma at ASH 2015 In combination with pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma at EHA 2015 Jun 2015 - Jun 2015: In combination with pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma at EHA 2015 More	Terminated	1/2	103	US	ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone, Pomalyst, Ricolinostat, Dexamethasone	Celgene	Multiple Myeloma	02/24	02/24
NCT05193851: Evaluate the Safety and Pharmacokinetics of Ricolinostat	Completed	1	12	RoW	ricolinostat	Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.	Peripheral Nervous System Diseases	01/22	01/23
NCT05229042: A Study to Investigate the Safety and Efficacy of Ricolinostat	Completed	1	10	RoW	Ricolinostat, Placebo	Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.	Peripheral Nervous System Diseases	11/23	11/23
NCT02787369: ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL	Active, not recruiting	1	3	US	ACY-1215, Ricolinostat, Ibrutinib, Imbruvica, Idelalisib, Zydelig	Dana-Farber Cancer Institute, Acetylon Pharmaceuticals Incorporated	Recurrent Chronic Lymphoid Leukemia	04/26	04/27
RCY-1497 / Regenacy
No trials found
ACY-957 / Regenacy
No trials found
RCY-1305 / Regenacy
No trials found